Kuwana, Japan

Atsushi Miyachi

USPTO Granted Patents = 1 

Average Co-Inventor Count = 18.0

ph-index = 1

Forward Citations = 11(Granted Patents)


Company Filing History:


Years Active: 2005

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Atsushi Miyachi: Innovator in Medicinal Chemistry

Introduction

Atsushi Miyachi is a notable inventor based in Kuwana, Japan. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target inflammatory and autoimmune diseases. His work has the potential to impact the treatment of various health conditions.

Latest Patents

Miyachi holds a patent for an "Antagonist of MCP-1 function, and compositions and methods of use thereof." This patent includes compounds of formula A and formula B, along with their pharmaceutically acceptable salts. The compounds serve as antagonists of MCP-1 function and are useful in the prevention and treatment of chronic or acute inflammatory or autoimmune diseases, such as multiple sclerosis. Additionally, they are beneficial in the prevention and treatment of allergic hypersensitivity disorders.

Career Highlights

Throughout his career, Atsushi Miyachi has worked with several prominent companies, including Telik, Inc. and Sanwa Kagaku Kenkyusho Co., Ltd. His experience in these organizations has allowed him to refine his expertise in medicinal chemistry and contribute to innovative solutions in healthcare.

Collaborations

Miyachi has collaborated with notable professionals in his field, including Edgardo Laborde and Louise Robinson. These partnerships have facilitated the exchange of ideas and advancements in research.

Conclusion

Atsushi Miyachi's contributions to medicinal chemistry, particularly through his patent on MCP-1 antagonists, highlight his role as an innovator in the field. His work continues to pave the way for advancements in the treatment of inflammatory and autoimmune diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…